Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

505.64
+3.330.66%
Post-market: 508.863.22+0.64%16:41 EDT
Volume:806.60K
Turnover:408.79M
Market Cap:128.29B
PE:29.43
High:511.51
Open:504.08
Low:503.94
Close:502.31
52wk High:560.25
52wk Low:400.86
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.81
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.34
PE(LYR):33.01

Loading ...

Vertex to Report Q3 2026 Financial Results, Host Conference Call and Webcast

Reuters
·
1 hour ago

Vortex Energy Launches Study on Natural Hydrogen and Helium at Robinsons River Salt Project

TIPRANKS
·
Oct 06

Vertex Minerals lodges 2026 corporate governance statement with ASX

TIPRANKS
·
Oct 02

Vortex Energy Expands Saskatchewan Portfolio with Meadows Project Acquisition

TIPRANKS
·
Oct 02

Vertex adds AI-focused independent director to board

TIPRANKS
·
Oct 02

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 02

S&P 500 Top and Bottom Performing Stocks at About 03:30 P.m. EDT

Reuters
·
Oct 02

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know

TradingKey
·
Oct 02

Movement Alert|Vertex Pharmaceuticals Declines 3.03% in Regular Trading, Trading at $506.63

Market Focus
·
Oct 02

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
Oct 02

Vertex appoints Saha to Board of Directors

TIPRANKS
·
Oct 01

Press Release: Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors

Dow Jones
·
Oct 01

Vertex Pharmaceuticals Price Target Raised to $615.00/Share from $585.00 by UBS

Dow Jones
·
Sep 29

UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating

MT Newswires Live
·
Sep 28

Vertex Minerals Sets October General Meeting for Shareholders

TIPRANKS
·
Sep 25

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 25

Goldman Sachs Reiterates Buy on Vertex as Inaxaplin Data De-Risk Outlook; $653 Price Target Reaffirmed

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 23

TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating

MT Newswires Live
·
Sep 23